We are live on ! Find out more
LAD icon

Lithia Motors

Positive
Neutral
Negative
Sentiment 3-Months
Positive 35.7%
Neutral 57.1%
Negative 7.1%

Neutral
GlobeNewsWire
5 hours ago
Lithia & Driveway (LAD) Schedules Release of Second Quarter 2026 Results
MEDFORD, Ore., July 14, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced its second quarter 2026 results will be released before the market opens on Wednesday, July 29, 2026. A conference call to discuss the earnings results is scheduled for the same day at 10:00 a.m. Eastern Time.
Lithia & Driveway (LAD) Schedules Release of Second Quarter 2026 Results
Neutral
Zacks Investment Research
18 days ago
Zacks Industry Outlook Lithia Motors, and Sonic
Lithia Motors, and Sonic have been highlighted in this Industry Outlook article.
Zacks Industry Outlook Lithia Motors, and Sonic
Negative
Zacks Investment Research
19 days ago
2 Auto Retailers Worth Watching Despite Purchasing Power Erosion
U.S. auto retail faces volume pressure and eroding purchasing power. Yet LAD and SAH stand out with smart acquisitions, digital push and shareholder returns.
2 Auto Retailers Worth Watching Despite Purchasing Power Erosion
Neutral
GlobeNewsWire
1 month ago
Lithia & Driveway (LAD) Rises to Number 123 on 2026 Fortune 500 List
MEDFORD, Ore., June 09, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced that it ranked No.
Lithia & Driveway (LAD) Rises to Number 123 on 2026 Fortune 500 List
Neutral
GlobeNewsWire
1 month ago
JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Positive
Zacks Investment Research
1 month ago
Why Is Lithia Motors (LAD) Up 1.9% Since Last Earnings Report?
Lithia Motors (LAD) reported earnings 30 days ago. What's next for the stock?
Why Is Lithia Motors (LAD) Up 1.9% Since Last Earnings Report?
Neutral
GlobeNewsWire
1 month ago
Lithia & Driveway (LAD) Announces Share Repurchase Authorization Increase
MEDFORD, Ore., May 26, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) announced today an increase to its share repurchase authorization of $500 million to bring the current remaining authorization to $726 million.
Lithia & Driveway (LAD) Announces Share Repurchase Authorization Increase
Neutral
Seeking Alpha
2 months ago
Lithia Motors, Inc. (LAD) Q1 2026 Earnings Call Transcript
Lithia Motors, Inc. (LAD) Q1 2026 Earnings Call Transcript
Lithia Motors, Inc. (LAD) Q1 2026 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Lithia Q1 Earnings Top Estimates on Higher Aftersales Margin
LAD Q1 tops EPS estimates as aftersales margins expand, offsetting weaker new-vehicle demand and rising costs amid shifting revenue mix.
Lithia Q1 Earnings Top Estimates on Higher Aftersales Margin
Positive
Zacks Investment Research
2 months ago
Compared to Estimates, Lithia Motors (LAD) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Lithia Motors (LAD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Lithia Motors (LAD) Q1 Earnings: A Look at Key Metrics